Vetbiobank Chien Revenue and Competitors
Estimated Revenue & Valuation
- Vetbiobank Chien's estimated annual revenue is currently $1.9M per year.
- Vetbiobank Chien's estimated revenue per employee is $155,000
Employee Data
- Vetbiobank Chien has 12 Employees.
- Vetbiobank Chien grew their employee count by -25% last year.
Vetbiobank Chien's People
Name | Title | Email/Phone |
---|
Vetbiobank Chien Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Vetbiobank Chien?
Vetbiobank is a biotech company specialized in veterinary regenerative medicine. For our customers and their animal companions (dogs, cats, horses), we are leveraging the unique biological potential of neonatal stem cells. Those stem cells deliver locally an appropriate set of bioactive messages to organise and promote the harmonious healing of injuries or dampen inflammatory chronic diseases. Funded in 2011, Vetbiobank has built its expertise on the experience of its founder, former expert in human cell therapy development, and cord blood derived stem cells. The mission of Vetbiobank is to provide veterinarians with biological products at the highest grade of quality to increase the odds of improving animal wellbeing. We accomplish this on a daily basis, driven by our vision to establish cell therapy products progressively as a first line treatment in veterinary daily practice. We work closely with surgeons team of VetAgro-Sup (veterinary univsersity in Lyon, France), our historical scientific partner since Vetbiobank's inception, to develop new therapeutic solutions in medical conditions insufficiently adressed by current standard of care.
keywords:N/AN/A
Total Funding
12
Number of Employees
$1.9M
Revenue (est)
-25%
Employee Growth %
N/A
Valuation
N/A
Accelerator